Brief: Ascletis Pharma Says Clinical Trial Application Of Asc42 Accepted For Review By China NMPA
06/09/2021 02:21
Sept 6 (Reuters) - Ascletis Pharma Inc 1672.HK :
* CLINICAL TRIAL APPLICATION OF ASC42 TO TREAT PRIMARY
BILIARY
CHOLANGITIS ACCEPTED FOR REVIEW BY CHINA NMPA
Further company coverage: 1672.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026